UniProt Q86UE8 · PDB · AlphaFold · Substrate: Casein · Clone: Catalytic (388-end)
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Bosutinib | 38.1% | 61.9% | 87.22 | 0.555 |
| 2 | Abemaciclib | 37.8% | 62.2% | 91.48 | 0.563 |
| 3 | Defactinib | 36.3% | 63.7% | 92.68 | 0.450 |
| 4 | Sunitinib | 35.4% | 64.6% | 91.73 | 0.524 |
| 5 | Midostaurin | 28.5% | 71.5% | 78.64 | 0.500 |
| 6 | Pacritinib | 19.5% | 80.5% | 88.64 | 0.452 |
| 7 | Vemurafenib | 19.2% | 80.8% | 96.49 | 0.598 |
| 8 | Capivasertib | 17.4% | 82.6% | 96.48 | 0.644 |
| 9 | Upadacitinib | 17.3% | 82.7% | 97.98 | 0.663 |
| 10 | Abrocitinib | 14.4% | 85.6% | 99.50 | 0.581 |
| 11 | Pemigatinib | 13.5% | 86.5% | 98.23 | 0.718 |
| 12 | Neratinib | 13.0% | 87.0% | 93.18 | 0.597 |
| 13 | Pralsetinib | 12.8% | 87.2% | 93.43 | 0.643 |
| 14 | Lorlatinib | 11.2% | 88.8% | 97.24 | 0.694 |
| 15 | Ruxolitinib | 10.7% | 89.3% | 98.25 | 0.592 |
| 16 | Fedratinib | 10.2% | 89.8% | 96.21 | 0.576 |
| 17 | Ribociclib | 7.9% | 92.1% | 99.25 | 0.729 |
| 18 | Gedatolisib | 7.6% | 92.4% | 99.75 | 0.611 |
| 19 | Fostamatinib | 7.2% | 92.8% | 96.74 | 0.613 |
| 20 | Asciminib | 6.9% | 93.1% | 100.00 | 0.602 |
Paralog block
No paralog group registered for this kinase.
EMT expression
- Mesenchymal log2(TPM+1): 4.32
- Epithelial log2(TPM+1): 4.17
- Fold change: 0.15
- Status: No significant change
Selectivity landscape vs inhibition on TLK2
Each point is one of the 92 approved drugs; color = inhibition % on TLK2.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…